Delivery Order SPE2DR25D1106-SPE2DR26FJC3B
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,957.42 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This non-competitive delivery order, with a firm fixed price structure, represents a child contract against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $41,055.70 delivery order to AmerisourceBergen Drug Corp on December 4, 2025, for the supply of Dupixent 300 mg/2 ml syringes. This competitively awarded, non-set-aside contract utilizes firm fixed-price pricing and requires completion by December 5, 2025. AmerisourceBergen will perform the work from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's existing Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,548.41 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes on October 21, 2025, with an ultimate completion date of October 22, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through...
- The Defense Logistics Agency (DLA) awarded a $10,274.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Dupixent 300 mg/2 ml syringes. The contract, with an ultimate completion date of November 5, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively awarded with no...
- The Defense Logistics Agency awarded a $27,437.03 delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The order is set to be completed by December 3, 2025, with performance at the vendor's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $29,840.94 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes. This firm fixed price, competitively awarded delivery order was issued on October 20, 2025, with an ultimate completion date of October 21, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $32,050.45 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on December 3, 2025, with a completion date of December 4, 2025. This competitively awarded, firm fixed-price contract represents a pediatric or adult pharmaceutical delivery under DLA's medical supply chain operations. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency has awarded a delivery order valued at $12,250.21 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes. This non-competitive, firm fixed-price delivery order, issued on November 12, 2025, with an ultimate completion date of November 13, 2025, will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,206.04 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes on December 5, 2025, with an ultimate completion date of December 8, 2025. This is a firm fixed-price, non-set-aside contract with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,783.94 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on November 18, 2025, with completion expected by November 19, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded competitively to the prime contractor at its corporate office location in Conshohocken, Pennsylvania. The order represents a single transaction under AmerisourceBergen's larger Indefinite...
- SPE2DR25D1106Indefinite Delivery Contract
- SPE2DR25D1106-SPE2DR26FJC3BDelivery Order
The Defense Logistics Agency (DLA) awarded a $36,484 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on December 4, 2025, with an ultimate completion date of December 5, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999 ceiling value and extends through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement across military and veteran healthcare systems. The company's comprehensive contract portfolio with the DLA Medical Supply Chain encompasses a wide range of pharmaceutical products, medical devices, vaccines, and specialized healthcare commodities across multiple therapeutic domains. This specific delivery order for Dupixent—a biologic medication used in immunology and dermatology—exemplifies the company's role in supplying specialized brand-name pharmaceuticals to support military healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $36.5k | 12/3/25 |